Completelyrevised and updated for 2017, the Physicians Cancer ChemotherapyDrug Manual is anup-to-date guide to the latest information on standard therapy and recentadvances in the field. Written by world-class experts in clinical cancertherapeutics, this essential reference provides a complete, easy-to-usecatalogue of over 100 drugs and commonly used drug regimensboth on- andoff-labelfor the treatment of all the major cancers.
Features & Benefits
Addition of12 new agents approved by the FDA within the pastyear and updates to new indications for several previously approved agents
Indications,drug doses and schedules, toxicities, and special considerations for each agentexpanded and revised
A specificchapter focused on antiemetic treatment regimens for both acute and delayednausea/vomiting
Diagrams ofdrug structures and pathways for many of the agents
Acomprehensive discussion of clinical pharmacology, special considerations,indications, and dosages
Coverstoxicity and drugdrug interactions
A sectionon chemotherapy regimens for all major cancers
Provides anoverview of the basic principles of cancer drug therapy
TABLE OF CONTENTS
Chapter 1 Principals of Cancer Chemotherapy
Chapter 2 Chemotherapeuticand Biologic Drugs
Chapter 3 Guidelinesfor Chemotherapy and Dosing Modifications
Chapter 4 CommonChemotherapy Regimens in Clinical Practice
Chapter 5 AntiemeticAgents for the Treatment of Chemotherapy-Induced Nausea and Vomiting
ABOUT THE AUTHOR
EdwardChu, MD-Professor of Medicine, Chief, Division ofHematology-Oncology, Deputy Director, University of Pittsburgh CancerInstitute, Pittsburgh, Pennsylvania
Dr. EdwardChu is a Professor of Medicine, Chief of the Division of Hematology-Oncology,and Deputy Director at the University of Pittsburgh CancerInstitute. He received his MD degree from BrownUniversity,where he also completed his residency training in Internal Medicine Residency. Hethen went to the National Cancer Institute in Bethesda, MDfor fellowship training in Medical Oncology. Following completion of hisfellowship, he remained at the NCI as a Senior Clinical Investigator. In 1996,he was recruited as a Professorof Medicine and Pharmacology atthe Yale University School of Medicine where he assumed the positions ofDirector of the VACTCancer Center,Associate Director of the YaleCancer Center,and co-Director of the Developmental Therapeutics Program at the YaleCancerCenter.
Dr. Chu iswell-known for his basic research that has investigated the determinants ofresistance to the fluoropyrimidine class of anticancer agents. In particular,his group has made seminal observations on the regulation of expression ofthymidylate synthase, a critical target in cancer chemotherapy, with specificfocus on elucidating novel translational regulatory mechanisms. In addition,his group is actively involved in developing novel compounds and strategies forthe treatment of colorectal cancer as well as other human malignancies. He hasworked closely with a number of drug companies to develop novel agents, andthese companies include Roche, Bristol-MyersSquibb, Astra Zeneca, Eli Lilly,Pharmacia, GlaxoSmithKline, Imclone, Vion, and Tularik. He serves on thescientific advisory boards of Advrx Pharmaceuticals, Celator, Etex,Phytoceutica, and Eximias, all of which are drug development companies.
He is theauthor of the Physicians Cancer Chemotherapy DrugManual, which is now in its sixth edition, and this drug manual includes acomprehensive review of all of the main drugs and drug regimens currently usedin clinical practice for oncology. He is the founding Editor-in-Chief of theclinical journal Clinical Colorectal Cancer and is the Chairman of theInternational Colorectal Congress, which is an annual international meetingfocusing on management and treatment of colorectal cancer.
No hay reseñas de clientes en este momento.